e-learning
resources
Glasgow 2004
Sunday 05.09.2004
Community acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Meta analysis of hospitalized patients with community-acquired pneumonia (CAP) treated with levofloxacin
G. Hoeffken, K. Roscher (Dresden, Bad Soden, Germany)
Source:
Annual Congress 2004 - Community acquired pneumonia
Session:
Community acquired pneumonia
Session type:
Thematic Poster Session
Number:
1190
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Hoeffken, K. Roscher (Dresden, Bad Soden, Germany). Meta analysis of hospitalized patients with community-acquired pneumonia (CAP) treated with levofloxacin. Eur Respir J 2004; 24: Suppl. 48, 1190
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients
Source: Annual Congress 2011 - COPD management
Year: 2011
Fluoroquinolone
versus
β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP)
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Legionella
pneumonia in patients hospitalized with community-acquired pneumonia (CAP) in Norway
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
The analysis of efficiency of amoxycillin/clavulanate (AC) usage at inpatients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 2s
Year: 2006
One year analysis of hospital-treated, community-acquired pneumonia (CAP)
Source: Eur Respir J 2002; 20: Suppl. 38, 356s
Year: 2002
Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment
Source: Annual Congress 2009 - Pulmonary infections
Year: 2009
The comparison of hospitalized healthcare-associated pneumonia with community-acquired pneumonia patients
Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Year: 2010
Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Mortality directly related to community-acquired pneumonia (CAP) in hospitalized patients: results from the community-acquired pneumonia organization (CAPO) international cohort study
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Discharge delay in patients with community-acquired pneumonia (CAP) treated with a pneumonia critical pathway
Source: Eur Respir J 2002; 20: Suppl. 38, 560s
Year: 2002
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Etiology of community-acquired pneumonia (CAP) in young hospital patients
Source: Eur Respir J 2002; 20: Suppl. 38, 356s
Year: 2002
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Use of ceftriaxone/sulbactame for treatment of mild-to-severe community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Treatment of airways disease
Year: 2009
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006
Are there radiographic differences between patients with community-acquired (CAP) and healthcare-associated pneumonias (HCAP)?
Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Year: 2010
Comparison of different models of azithromycin treatment of patients with no severe community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 166s
Year: 2006
Heliox-therapy of patients with execerbation of COPD and community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 106s
Year: 2006
Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept